JP2007502258A - バニロイド受容体モジュレーターとして用いるためのピペリジン/シクロヘキサンカルボキサミド誘導体 - Google Patents
バニロイド受容体モジュレーターとして用いるためのピペリジン/シクロヘキサンカルボキサミド誘導体 Download PDFInfo
- Publication number
- JP2007502258A JP2007502258A JP2006522995A JP2006522995A JP2007502258A JP 2007502258 A JP2007502258 A JP 2007502258A JP 2006522995 A JP2006522995 A JP 2006522995A JP 2006522995 A JP2006522995 A JP 2006522995A JP 2007502258 A JP2007502258 A JP 2007502258A
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- piperidine
- pharmaceutically acceptable
- solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010062740 TRPV Cation Channels Proteins 0.000 title description 17
- 102000011040 TRPV Cation Channels Human genes 0.000 title description 16
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 title 2
- PNZXMIKHJXIPEK-UHFFFAOYSA-N cyclohexanecarboxamide Chemical class NC(=O)C1CCCCC1 PNZXMIKHJXIPEK-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 93
- 150000003839 salts Chemical class 0.000 claims abstract description 33
- 238000000034 method Methods 0.000 claims abstract description 27
- 239000012453 solvate Substances 0.000 claims abstract description 25
- 239000003814 drug Substances 0.000 claims abstract description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 8
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 claims description 6
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 4
- 230000008485 antagonism Effects 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 125000006239 protecting group Chemical group 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 125000004607 1,2,3,4-tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 claims description 2
- AVQIKBITMCCIBE-UHFFFAOYSA-N 4-phenyl-n-quinolin-7-ylpiperidine-1-carboxamide Chemical compound C=1C=C2C=CC=NC2=CC=1NC(=O)N(CC1)CCC1C1=CC=CC=C1 AVQIKBITMCCIBE-UHFFFAOYSA-N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- GZZRETUOZFVINX-UHFFFAOYSA-N n-isoquinolin-5-yl-1-[5-(trifluoromethyl)pyridin-2-yl]piperidine-4-carboxamide Chemical compound N1=CC(C(F)(F)F)=CC=C1N1CCC(C(=O)NC=2C3=CC=NC=C3C=CC=2)CC1 GZZRETUOZFVINX-UHFFFAOYSA-N 0.000 claims description 2
- IHHAYFCNKFGOEF-UHFFFAOYSA-N n-quinolin-7-yl-1-[5-(trifluoromethyl)pyridin-2-yl]piperidine-4-carboxamide Chemical compound N1=CC(C(F)(F)F)=CC=C1N1CCC(C(=O)NC=2C=C3N=CC=CC3=CC=2)CC1 IHHAYFCNKFGOEF-UHFFFAOYSA-N 0.000 claims description 2
- WETLUMAAJBVHFJ-UHFFFAOYSA-N n-quinolin-7-yl-1-[6-(trifluoromethyl)pyridin-2-yl]piperidine-4-carboxamide Chemical compound FC(F)(F)C1=CC=CC(N2CCC(CC2)C(=O)NC=2C=C3N=CC=CC3=CC=2)=N1 WETLUMAAJBVHFJ-UHFFFAOYSA-N 0.000 claims description 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 230000009286 beneficial effect Effects 0.000 claims 2
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 239000000203 mixture Substances 0.000 description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 11
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
- 208000002193 Pain Diseases 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- -1 4-hydroxy-3-methoxybenzyl) group Chemical group 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 229960002504 capsaicin Drugs 0.000 description 6
- 235000017663 capsaicin Nutrition 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 125000005843 halogen group Chemical group 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 125000001309 chloro group Chemical group Cl* 0.000 description 5
- BWBDUUYXWHNBJW-UHFFFAOYSA-N 1-(4-chlorophenyl)piperidine-4-carboxylic acid Chemical compound C1CC(C(=O)O)CCN1C1=CC=C(Cl)C=C1 BWBDUUYXWHNBJW-UHFFFAOYSA-N 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 125000001246 bromo group Chemical group Br* 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 125000001153 fluoro group Chemical group F* 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- XUNJKWXYQMKWHJ-UHFFFAOYSA-N 5-amino-1-methylquinolin-2-one Chemical compound C1=CC(N)=C2C=CC(=O)N(C)C2=C1 XUNJKWXYQMKWHJ-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000004454 Hyperalgesia Diseases 0.000 description 3
- 208000035154 Hyperesthesia Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000003638 chemical reducing agent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- PWLPLUATWXICAC-UHFFFAOYSA-N 1,2-benzoxazol-6-amine Chemical compound NC1=CC=C2C=NOC2=C1 PWLPLUATWXICAC-UHFFFAOYSA-N 0.000 description 2
- RSOHLDYQGWVCCJ-UHFFFAOYSA-N 1-(1,3-benzothiazol-2-yl)piperidine-4-carboxylic acid Chemical compound C1CC(C(=O)O)CCN1C1=NC2=CC=CC=C2S1 RSOHLDYQGWVCCJ-UHFFFAOYSA-N 0.000 description 2
- PDZXXMJPTWHDHG-UHFFFAOYSA-N 1-(2,4-dichlorophenyl)piperidine-4-carboxylic acid Chemical compound C1CC(C(=O)O)CCN1C1=CC=C(Cl)C=C1Cl PDZXXMJPTWHDHG-UHFFFAOYSA-N 0.000 description 2
- CSURNPBDXKECDT-UHFFFAOYSA-N 1-(2,4-difluorophenyl)piperidine-4-carboxylic acid Chemical compound C1CC(C(=O)O)CCN1C1=CC=C(F)C=C1F CSURNPBDXKECDT-UHFFFAOYSA-N 0.000 description 2
- AUSMMVHIORMADR-UHFFFAOYSA-N 1-(2,5-dichlorophenyl)piperidine-4-carboxylic acid Chemical compound C1CC(C(=O)O)CCN1C1=CC(Cl)=CC=C1Cl AUSMMVHIORMADR-UHFFFAOYSA-N 0.000 description 2
- PZEVVUIQWUAGES-UHFFFAOYSA-N 1-(2-chloro-4-fluorophenyl)piperidine-4-carboxylic acid Chemical compound C1CC(C(=O)O)CCN1C1=CC=C(F)C=C1Cl PZEVVUIQWUAGES-UHFFFAOYSA-N 0.000 description 2
- NXKMPLQQNPQWLA-UHFFFAOYSA-N 1-(3,4-dichlorophenyl)piperidine-4-carboxylic acid Chemical compound C1CC(C(=O)O)CCN1C1=CC=C(Cl)C(Cl)=C1 NXKMPLQQNPQWLA-UHFFFAOYSA-N 0.000 description 2
- FMNFIIFBVCLQBQ-UHFFFAOYSA-N 1-(3,5-dichlorophenyl)piperidine-4-carboxylic acid Chemical compound C1CC(C(=O)O)CCN1C1=CC(Cl)=CC(Cl)=C1 FMNFIIFBVCLQBQ-UHFFFAOYSA-N 0.000 description 2
- ZHKRRELTGHBABY-UHFFFAOYSA-N 1-(3-chlorophenyl)piperidine-4-carboxylic acid Chemical compound C1CC(C(=O)O)CCN1C1=CC=CC(Cl)=C1 ZHKRRELTGHBABY-UHFFFAOYSA-N 0.000 description 2
- ODWDCJSINGSMBD-UHFFFAOYSA-N 1-(4-chloro-2-methylphenyl)piperidine-4-carboxylic acid Chemical compound CC1=CC(Cl)=CC=C1N1CCC(C(O)=O)CC1 ODWDCJSINGSMBD-UHFFFAOYSA-N 0.000 description 2
- NKARGXJAQBSBCA-UHFFFAOYSA-N 1-(4-chloro-3-fluorophenyl)piperidine-4-carboxylic acid Chemical compound C1CC(C(=O)O)CCN1C1=CC=C(Cl)C(F)=C1 NKARGXJAQBSBCA-UHFFFAOYSA-N 0.000 description 2
- DWZOONHZGMRIPO-UHFFFAOYSA-N 1-(4-chlorophenyl)-n-(1-methyl-2-oxoquinolin-5-yl)piperidine-4-carboxamide Chemical compound C=12C=CC(=O)N(C)C2=CC=CC=1NC(=O)C(CC1)CCN1C1=CC=C(Cl)C=C1 DWZOONHZGMRIPO-UHFFFAOYSA-N 0.000 description 2
- KWCXEOVSAJSXRS-UHFFFAOYSA-N 1-(4-cyanophenyl)piperidine-4-carboxylic acid Chemical compound C1CC(C(=O)O)CCN1C1=CC=C(C#N)C=C1 KWCXEOVSAJSXRS-UHFFFAOYSA-N 0.000 description 2
- OSZVYVOEZNGDLY-UHFFFAOYSA-N 1-(4-fluorophenyl)piperidine-4-carboxylic acid Chemical compound C1CC(C(=O)O)CCN1C1=CC=C(F)C=C1 OSZVYVOEZNGDLY-UHFFFAOYSA-N 0.000 description 2
- KORJAGBJOHCZCU-UHFFFAOYSA-N 1-(4-methoxyphenyl)piperidine-4-carboxylic acid Chemical compound C1=CC(OC)=CC=C1N1CCC(C(O)=O)CC1 KORJAGBJOHCZCU-UHFFFAOYSA-N 0.000 description 2
- WTDYDDZGBUZEEB-UHFFFAOYSA-N 1-(4-methylphenyl)piperidine-4-carboxylic acid Chemical compound C1=CC(C)=CC=C1N1CCC(C(O)=O)CC1 WTDYDDZGBUZEEB-UHFFFAOYSA-N 0.000 description 2
- YOSRZAOSDZTMAM-UHFFFAOYSA-N 1-(5-chloropyridin-2-yl)piperidine-4-carboxylic acid Chemical compound C1CC(C(=O)O)CCN1C1=CC=C(Cl)C=N1 YOSRZAOSDZTMAM-UHFFFAOYSA-N 0.000 description 2
- DLQSEGIGDCETIS-UHFFFAOYSA-N 1-(6-chloropyridazin-3-yl)piperidine-4-carboxylic acid Chemical compound C1CC(C(=O)O)CCN1C1=CC=C(Cl)N=N1 DLQSEGIGDCETIS-UHFFFAOYSA-N 0.000 description 2
- QQLHPDDWFJFRBL-UHFFFAOYSA-N 1-[(2,4-dichlorophenyl)methyl]piperidin-1-ium-4-carboxylate Chemical compound C1CC(C(=O)O)CCN1CC1=CC=C(Cl)C=C1Cl QQLHPDDWFJFRBL-UHFFFAOYSA-N 0.000 description 2
- IWGYNCJBXZCOMM-UHFFFAOYSA-N 1-[(2-chlorophenyl)methyl]piperidine-4-carboxylic acid Chemical compound C1CC(C(=O)O)CCN1CC1=CC=CC=C1Cl IWGYNCJBXZCOMM-UHFFFAOYSA-N 0.000 description 2
- PUGKULNOZQXTSX-UHFFFAOYSA-N 1-[(3-chlorophenyl)methyl]piperidin-1-ium-4-carboxylate Chemical compound C1CC(C(=O)O)CCN1CC1=CC=CC(Cl)=C1 PUGKULNOZQXTSX-UHFFFAOYSA-N 0.000 description 2
- FCNZWHCTMHUWMT-UHFFFAOYSA-N 1-[(4-chlorophenyl)methyl]piperidine-4-carboxylic acid Chemical compound C1CC(C(=O)O)CCN1CC1=CC=C(Cl)C=C1 FCNZWHCTMHUWMT-UHFFFAOYSA-N 0.000 description 2
- BGNKYDHEZJLXEU-UHFFFAOYSA-N 1-[3-(trifluoromethyl)pyridin-2-yl]piperidine-4-carboxylic acid Chemical compound C1CC(C(=O)O)CCN1C1=NC=CC=C1C(F)(F)F BGNKYDHEZJLXEU-UHFFFAOYSA-N 0.000 description 2
- GBLCZMUANRHJIZ-UHFFFAOYSA-N 1-[3-chloro-5-(trifluoromethyl)pyridin-1-ium-2-yl]piperidine-4-carboxylate Chemical compound C1CC(C(=O)[O-])CCN1C1=[NH+]C=C(C(F)(F)F)C=C1Cl GBLCZMUANRHJIZ-UHFFFAOYSA-N 0.000 description 2
- CZYGUSOIAORVRC-UHFFFAOYSA-N 1-[4-(trifluoromethyl)phenyl]piperidine-4-carboxylic acid Chemical compound C1CC(C(=O)O)CCN1C1=CC=C(C(F)(F)F)C=C1 CZYGUSOIAORVRC-UHFFFAOYSA-N 0.000 description 2
- QYAIISDWPUEPHG-UHFFFAOYSA-N 1-[4-(trifluoromethyl)pyrimidin-2-yl]piperidine-4-carboxylic acid Chemical compound C1CC(C(=O)O)CCN1C1=NC=CC(C(F)(F)F)=N1 QYAIISDWPUEPHG-UHFFFAOYSA-N 0.000 description 2
- UEWKDOPYRFJYPV-UHFFFAOYSA-N 1-[4-chloro-2-(trifluoromethyl)phenyl]piperidine-4-carboxylic acid Chemical compound C1CC(C(=O)O)CCN1C1=CC=C(Cl)C=C1C(F)(F)F UEWKDOPYRFJYPV-UHFFFAOYSA-N 0.000 description 2
- KNDSIDUPVUCATQ-UHFFFAOYSA-N 1-[5-(trifluoromethyl)pyridin-2-yl]piperidine-4-carboxylic acid Chemical compound C1CC(C(=O)O)CCN1C1=CC=C(C(F)(F)F)C=N1 KNDSIDUPVUCATQ-UHFFFAOYSA-N 0.000 description 2
- VCOCIENQYZVMSW-UHFFFAOYSA-N 1-[6-methyl-4-(trifluoromethyl)pyridin-2-yl]piperidine-4-carboxylic acid Chemical compound CC1=CC(C(F)(F)F)=CC(N2CCC(CC2)C(O)=O)=N1 VCOCIENQYZVMSW-UHFFFAOYSA-N 0.000 description 2
- ZMVSVQMWFTZSJQ-UHFFFAOYSA-N 1-benzylpiperidine-4-carboxylic acid Chemical compound C1CC(C(=O)O)CCN1CC1=CC=CC=C1 ZMVSVQMWFTZSJQ-UHFFFAOYSA-N 0.000 description 2
- CZWVDQJRKFSOAG-UHFFFAOYSA-M 1-methyl-5-nitroquinolin-1-ium;iodide Chemical compound [I-].C1=CC=C2[N+](C)=CC=CC2=C1[N+]([O-])=O CZWVDQJRKFSOAG-UHFFFAOYSA-M 0.000 description 2
- FNEPMMJDCROXSK-UHFFFAOYSA-N 1-methyl-5-nitroquinolin-2-one Chemical compound C1=CC([N+]([O-])=O)=C2C=CC(=O)N(C)C2=C1 FNEPMMJDCROXSK-UHFFFAOYSA-N 0.000 description 2
- DYVXURZASBPYFR-UHFFFAOYSA-N 1-pyrimidin-2-ylpiperidine-4-carboxylic acid Chemical compound C1CC(C(=O)O)CCN1C1=NC=CC=N1 DYVXURZASBPYFR-UHFFFAOYSA-N 0.000 description 2
- WAIVPCOVKZPTFI-UHFFFAOYSA-N 4-(4-chlorophenyl)-n-quinolin-5-ylcyclohexane-1-carboxamide Chemical compound C1=CC(Cl)=CC=C1C1CCC(C(=O)NC=2C3=CC=CN=C3C=CC=2)CC1 WAIVPCOVKZPTFI-UHFFFAOYSA-N 0.000 description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 2
- 208000000094 Chronic Pain Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 206010046543 Urinary incontinence Diseases 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 208000000718 duodenal ulcer Diseases 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- XMIAFAKRAAMSGX-UHFFFAOYSA-N quinolin-5-amine Chemical compound C1=CC=C2C(N)=CC=CC2=N1 XMIAFAKRAAMSGX-UHFFFAOYSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- 239000000085 vanilloid receptor antagonist Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- NHDODQWIKUYWMW-UHFFFAOYSA-N 1-bromo-4-chlorobenzene Chemical compound ClC1=CC=C(Br)C=C1 NHDODQWIKUYWMW-UHFFFAOYSA-N 0.000 description 1
- KBDMNBWTHOKXQA-UHFFFAOYSA-N 1-methylisoquinolin-5-amine Chemical compound C1=CC=C2C(C)=NC=CC2=C1N KBDMNBWTHOKXQA-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- GPWQHYMVUZYWIK-UHFFFAOYSA-N 2-methyl-1,3-benzothiazol-5-amine Chemical compound NC1=CC=C2SC(C)=NC2=C1 GPWQHYMVUZYWIK-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- NXXDIEYTMQYWJU-UHFFFAOYSA-N 4-(4-chlorophenyl)cyclohexane-1-carboxylic acid Chemical compound C1CC(C(=O)O)CCC1C1=CC=C(Cl)C=C1 NXXDIEYTMQYWJU-UHFFFAOYSA-N 0.000 description 1
- DTVYNUOOZIKEEX-UHFFFAOYSA-N 5-aminoisoquinoline Chemical compound N1=CC=C2C(N)=CC=CC2=C1 DTVYNUOOZIKEEX-UHFFFAOYSA-N 0.000 description 1
- NDDZXHOCOKCNBM-UHFFFAOYSA-N 5-nitroquinoline Chemical compound C1=CC=C2C([N+](=O)[O-])=CC=CC2=N1 NDDZXHOCOKCNBM-UHFFFAOYSA-N 0.000 description 1
- WIYPTBLUSSLGIV-UHFFFAOYSA-N 6-nitro-1,2-benzoxazole Chemical compound [O-][N+](=O)C1=CC=C2C=NOC2=C1 WIYPTBLUSSLGIV-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 208000023514 Barrett esophagus Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 206010030216 Oesophagitis Diseases 0.000 description 1
- 208000000450 Pelvic Pain Diseases 0.000 description 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010038419 Renal colic Diseases 0.000 description 1
- 208000008765 Sciatica Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 108010025083 TRPV1 receptor Proteins 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- PTPUOMXKXCCSEN-UHFFFAOYSA-N acetyloxymethyl 2-[2-[2-[5-[3-(acetyloxymethoxy)-2,7-dichloro-6-oxoxanthen-9-yl]-2-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]phenoxy]ethoxy]-n-[2-(acetyloxymethoxy)-2-oxoethyl]-4-methylanilino]acetate Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=C(C)C=C1OCCOC1=CC(C2=C3C=C(Cl)C(=O)C=C3OC3=CC(OCOC(C)=O)=C(Cl)C=C32)=CC=C1N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O PTPUOMXKXCCSEN-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 238000010976 amide bond formation reaction Methods 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 230000007885 bronchoconstriction Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- DRCMAZOSEIMCHM-UHFFFAOYSA-N capsazepine Chemical compound C1C=2C=C(O)C(O)=CC=2CCCN1C(=S)NCCC1=CC=C(Cl)C=C1 DRCMAZOSEIMCHM-UHFFFAOYSA-N 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 208000003295 carpal tunnel syndrome Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 208000006881 esophagitis Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000003555 thioacetals Chemical class 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 208000009935 visceral pain Diseases 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
- C07C311/46—Y being a hydrogen or a carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
- C07C317/38—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atom of at least one amino group being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfones
- C07C317/40—Y being a hydrogen or a carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Abstract
Description
Pは、フェニル、キノリニル、イソキノリニル、1,2,3,4−テトラヒドロキノリニル、ベンゾイソキサゾリルまたはベンゾチアゾリルであり;
P’は、フェニル、ピリジニル、ピリミジニル、ピリダジニルまたはベンゾチアゾリルであり;
R1およびR2は、同じであっても異なっていてもよく、アルキル、アルコキシ、ハロ、−CF3、−OCF3、−OH、=O、−CN、−NO2、−SO2NH2、−SO2R3または−NR3R4であり;
R3およびR4は、同じであっても異なっていてもよく、−Hまたはアルキルであり;
mは0または1であり;
nは0、1、2、3、4または5であり;および
XはNまたはCHである]
またはその医薬上許容される塩もしくは溶媒和物を提供する:
ただし、該式(I)で示される化合物は:
4−フェニル−N−キノリン−7−イル−ピペリジン−1−カルボキサミド;
N−キノリン−7−イル−1−(5−トリフルオロメチルピリド−2−イル)−ピペリジン−4−カルボキサミド;
N−キノリン−7−イル−1−(6−トリフルオロメチルピリド−2−イル)−ピペリジン−4−カルボキサミド;
N−イソキノリン−5−イル−1−(5−トリフルオロメチルピリド−2−イル)−ピペリジン−4−カルボキサミド;および
4−(4−クロロフェニル)−N−(2−メチルベンゾチアゾール−5−イル)シクロヘキサン−1−カルボキサミド;
から選択される化合物を除く。
好ましくは、P’はフェニルである。好ましくは、P’はピリジニルまたはピリミジニルである。
好ましくは、R1は、アルキル、例えばメチル、ハロ、例えばクロロまたはブロモ、=O、−SO2NH2、または−SO2Meである。
好ましくは、R2は、アルキル、アルコキシ、例えばメトキシ、ハロ、例えばクロロまたはフルオロ、−CF3または−CNである。
好ましくは、R4は−Hまたはメチルである。
好ましくは、mは0である。好ましくは、mは1である。
好ましくは、nは0、1または2である。
好ましくは、XはNである。好ましくは、XはCHである。
本発明の特に好ましい化合物は、実施例1、3、8、16〜25、28〜29、31〜33、43〜45を含む。
上記したように、式(I)で示される化合物は、塩、特に医薬上許容される塩を形成することができる。適当な医薬上許容される塩は、当該分野で慣用的に用いられるものであり、J. Pharm. Sci., 1977, 66, 1-19に記載のもの、例えば酸付加塩を含む。
適当な医薬上許容される酸付加塩は、無機酸、例えば、塩酸、臭化水素酸、オルトリン酸または硫酸との塩、または有機酸、例えばメタンスルホン酸、トルエンスルホン酸、酢酸、プロピオン酸、乳酸、クエン酸、フマル酸、リンゴ酸、コハク酸、サリチル酸、マレイン酸、グリセロリン酸またはアセチルサリチル酸との塩を含む。
適当な溶媒和物は、医薬上許容される溶媒、例えば水和物を含む。
溶媒和物は、化学量論的溶媒和物および非化学量論的溶媒和物を含む。
本明細書で用いられる「ハロ」なる用語は、特記しない限り、フッ素(「フルオロ」)、塩素(「クロロ」)、臭素(「ブロモ」)またはヨウ素(「ヨウド」)から選択される基である。
(a)式(II):
で示される化合物を、式(III):
で示される化合物と反応させ、ついで、その後要すれば、以下の工程:
(i)式(I)で示される化合物を他の式(I)で示される化合物に変換すること;
(ii)いずれの保護基を除去すること;
(iii)形成した化合物の塩または溶媒和物を調製すること;
の1つ以上を行うことを含む方法を提供する。
式(IV)で示される化合物は、市販されているか、あるいは、選択された特定の基により決定される条件下、文献の方法、例えばLarock R. F.「Comprehensive Organic Transformations」, New York, Wiley (1999)に記載の方法に従って調製することができる。
で示される化合物の加水分解により調製することができる。適当な加水分解剤は、塩酸である。適当な溶媒はジオキサンである。
(i) R1基を他のR1基に変換すること;および
(ii) R2基を他のR2基に変換すること;
の組み合わせを含む。
上記した変換(i)−(ii)は、選択された特定の基により決定される条件下、いずれの適当な方法を用いて行うことができる。
医薬上許容される塩は、適当な酸または酸誘導体との反応により慣用的に調製されてもよい。
特に、本発明は痛みの治療または予防において用いるための式(I)で示される化合物またはその医薬上許容される塩もしくは溶媒和物を提供する。
治療において本発明の化合物を用いるために、通常は、標準的な薬務に従って医薬組成物に処方されるだろう。かくして、本発明は、式(I)で示される化合物またはその医薬上許容される塩もしくは溶媒和物、およびそのための医薬上許容される担体または賦形剤を含む、医薬組成物を提供する。
有利には、局所麻酔薬、防腐剤、および緩衝剤のようなアジュバントはビヒクルに溶解する。安定性を高めるために、組成物をバイアルへ充填後凍結し、ついで真空で水を除去することができる。非経口懸濁液は、化合物をビヒクルに溶かす代わりに懸濁させ、滅菌処理が濾過によりなし得ないことを除き、実質的には同じ方法で調製される。化合物は滅菌ビヒクルに懸濁させる前に、エチレンオキシドに曝すことにより滅菌することができる。有利には、界面活性剤または湿潤剤を、化合物の均一分布を促進するために組成物中に含ませる。
上記した障害の治療に用いる化合物の投与量は、一般に、疾患の重症度、患者の体重、および他の同様な因子により変化するだろう。全身投与の場合、体重1キログラムあたり0.01mg〜100mgの投与量レベルが、痛みの治療において有用である。しかしながら、一般的な指針として、適当な単位用量は0.05〜1000mg、より適当には0.05〜20、20〜250、または0.1〜500.0mg、例えば0.2〜5および0.1〜250mgであってもよく、かかる単位用量は、1日に1回以上、例えば1日に2または3回投与されてもよく、結果として1日の全投与量は、約0.5〜1000mgの範囲内であり、かかる治療は数週間、または数ヶ月に及んでよい。
本明細書で引用した特許および特許出願を含め、すべての刊行物を出典明示により本明細書に組み入れる。
省略記号
DMF=ジメチルホルムアミド、DCM=ジクロロメタン、
BINAP=2,2’−ビス(ジフェニルホスフィノ)−1,1’−ビナフチル、
NaOH=水酸化ナトリウム、LiOH=水酸化リチウム
5−ニトロ−1−メチルキノリニウムヨウダイド(D1)
DMF(8ml)中の5−ニトロキノリン(5g、0.028mol)およびヨウドメタン(5.4ml、0.086mol)の混合物を、40℃に加熱した。2時間後、粘性の暗色沈殿が形成し、混合物を冷却し、アセトンで希釈した。固体を濾過し、アセトンで洗浄し、乾燥して標題化合物を橙色固体として得た。
5−ニトロ−1−メチル−2−(1H)−キノリノン(D2)
温水(90ml)中のD1(8.47g、0.03mol)の溶液を、45℃で維持した10%のNaOH中のフェリシアン化カリウム(33.6g、0.1mol)の溶液に滴下した。5時間後、温度を60℃に上昇させ、溶液を24時間加熱した。溶液を氷浴で15分間冷却し、灰緑色固体を濾過し、水で洗浄し、乾燥した。粗固体を最小量のDCM中に溶解し、シリカゲルで濾過し、酢酸エチルで、さらに生成物を溶出されなくなるまで洗浄した。減圧下で蒸発させて、標題化合物を暗橙色固体として得た。
5−アミノ−1−メチル−2−(1H)−キノリノン(D3)
エタノール(100ml)およびDMF(30ml)中のD2(2.59g、0.13mol)を、10%の炭素担持パラジウム(1g、50%w/w水)で処理した。混合物を、8時間大気圧下で水素化し、触媒を除去した後、減圧下で濃縮した。エーテルでトリチュレートして、標題化合物を淡黄色固体して得た。
1−(4−クロロフェニル)ピペリジン−4−カルボン酸,エチルエステル(D4)
ラセミBINAP(2.25g、0.0036mol)、酢酸パラジウム(0.82g、3.65mmol)および炭酸セシウム(16.86g、0.051mol)を、1、4−ジオキサン(100ml)中に懸濁させ、45分間、超音波で処理した。4−ブロモ−クロロベンゼン(5g、26.12mmol)およびエチルイソニペコアセテート(4.11g、26.12mmol)を、1,4−ジオキサン(100ml)中の溶液として加えた。混合物を、105℃で16時間加熱した。冷却して、溶媒を除去し、残渣を水(100ml)およびジエチルエーテル(100ml)間で分配した。水層をエーテルで抽出した。合した層を乾燥(Na2SO4)し、減圧下で濃縮した。フラッシュクロマトグラフィー(酢酸エチル/石油エーテル)により精製して、標題化合物を油として得た。
1−(4−クロロ−フェニル)−ピペリジン−4−カルボン酸(D5)
1NのLiOH(30ml)およびジオキサン(30ml)中のD4(1.82g、0.0067mol)溶液を、室温にて16時間撹拌し、ついで、減圧下で蒸発させた。1MのHClおよび酢酸エチルで処理し、標題化合物を黄色固体として得た。
1−(3−クロロフェニル)−ピペリジン−4−カルボン酸(D6)
1−(4−シアノフェニル)−ピペリジン−4−カルボン酸(D7)
1−(4−フルオロフェニル)−ピペリジン−4−カルボン酸(D8)
1−(4−メチルフェニル)−ピペリジン−4−カルボン酸(D9)
1−(4−メトキシフェニル)−ピペリジン−4−カルボン酸(D10)
1−(4−トリフルオロメチルフェニル)−ピペリジン−4−カルボン酸(D11)
1−(4−クロロ−2−メチルフェニル)−ピペリジン−4−カルボン酸(D12)
1−(4−クロロ−2−トリフルオロメチルフェニル)−ピペリジン−4−カルボン酸(D13)
1−(2,4−ジクロロフェニル)−ピペリジン−4−カルボン酸(D14)
1−(2,5−ジクロロフェニル)−ピペリジン−4−カルボン酸(D15)
1−(3,5−ジクロロフェニル)−ピペリジン−4−カルボン酸(D16)
1−(3,4−ジクロロ−フェニル)−ピペリジン−4−カルボン酸(D17)
1−(2−クロロ−4−フルオロフェニル)−ピペリジン−4−カルボン酸(D18)
1−(4−クロロ−3−フルオロフェニル)−ピペリジン−4−カルボン酸(D19)
1−(2,4−ジフルオロフェニル)−ピペリジン−4−カルボン酸(D20)
1−(5−クロロピリジン−2−イル)−ピペリジン−4−カルボン酸(D21)
1−(5−トリフルオロメチルピリジン−2−イル)−ピペリジン−4−カルボン酸(D22)
1−(3−クロロ−5−トリフルオロメチルピリジン−2−イル)−ピペリジン−4−カルボン酸(D23)
1−(3−トリフルオロメチルピリジン−2−イル)−ピペリジン−4−カルボン酸(D24)
1−(6−メチル−4−トリフルオロメチルピリジン−2−イル)−ピペリジン−4−カルボン酸(D25)
1−(ピリミジン−2−イル)−ピペリジン−4−カルボン酸(D26)
1−(4−トリフルオロメチルピリミジン−2−イル)−ピペリジン−4−カルボン酸(D27)
1−(6クロロピリダジン−3−イル)−ピペリジン−4−カルボン酸(D28)
1−(ベンゾチアゾール−2−イル)−ピペリジン−4−カルボン酸(D29)
1−(ベンジル)−ピペリジン−4−カルボン酸(D30)
1−(2−クロロベンジル)−ピペリジン−4−カルボン酸(D31)
1−(3−クロロベンジル)−ピペリジン−4−カルボン酸(D32)
1−(4−クロロベンジル)−ピペリジン−4−カルボン酸(D33)
1−(2,4−ジクロロベンジル)−ピペリジン−4−カルボン酸(D34)
6−アミノベンズイソキサゾール(D35)
6−ニトロベンゾイソキサゾール(F.Hollfelder et al., J.Org. Chem., 2001, 66, 5866)から、WO2004/024710の方法を用いて還元することにより標題化合物を調製した。
5−アミノ−2−メチルベンゾチアゾール、5−アミノイソキノリンおよび5−アミノキノリンは、市販されている。5−アミノ−1−メチルイソキノリンは、WO2004/024710に従って調製した。
1−(4−クロロフェニル)−N−(1−メチル−2−オキソ−1,2−ジヒドロ−5−キノリニル)−4−ピペリジンカルボキサミド(E1)
DCM(5ml)中の1−(4−クロロフェニル)−4−ピペリジンカルボン酸(D5、150mg、0.63mM)の懸濁液を、アルゴン雰囲気下、塩化オキサリル(0.164ml、1.88mM)および1滴のDMFで処理した。2時間後、溶液を減圧下で濃縮し、ついで、DCM(10ml)中に再び溶解した。溶液を氷浴で冷却し、5−アミノ−1−メチル−2−(1H)−キノリノン、D3(109mg、0.03mmol)およびピリジン(0.061ml、0.75mmol)の溶液で処理した。混合物を25℃に約2時間保持し、ついで、さらに2時間45℃に保持し、再び25℃に24時間保持した。形成した粘性の沈殿を、遠心分離により除去して、DCM、エーテルで洗浄し、乾燥して、標題化合物を淡黄色固体として得た(156mg、63%)。MH+396、394
4−(4−クロロフェニル)−N−5−キノリニルシクロヘキサンカルボキサミド(E2)
N,N−ジメチルアセトアミド(1mL)中の4−(4−クロロフェニル)シクロヘキサンカルボン酸(11.9mg、0.05mmol)の溶液に、塩化チオニル(2.0MのDCM溶液(25μL、0.05mmol)を加え、得られた溶液を30分間撹拌した。N,N−ジメチルアセトアミド(0.5mL)中の5−アミノキノリン(7.2mg、0.05mmol)およびジイソプロピルエチルアミン(19μL、0.15mmol)を加えた。混合物を16時間撹拌し、ついで、減圧下で蒸発させた。残渣を逆相HPLCにより精製して、標題化合物を白色固体として得た(6.0mg、33%)。MH+=365、363
(a)インビトロアッセイ
上記したように、本発明の化合物はバニロイド受容体(VR1)アンタゴニストであり、したがって、有用な医薬特性を有する。バニロイド受容体(VR1)アンタゴニスト活性は、慣用的な方法、例えばD. Le Bars, M. Gozarin and S. W. Cadden, [Pharmacological Reviews, 2001, 53(4), 597-652]などの標準的な参考文献、または本明細書で記載した他の文献中で開示されている方法を用いて、個々の化合物について確認し、立証をすることができる。
ヒトVR1を安定に発現する、形質移入された星状細胞腫1321N1細胞を、FLIPRプレートへ25,000セル/ウェル(96−ウェルプレート)で蒔き、一晩培養した。
インビトロでpKb>7.0を有する化合物を、モデル(a)に従って、痛覚過敏のモデルにおいても試験し(詳細はWO2004/024710を参照のこと)、活性であることが示された。実施例1は、5mg/kgpoの投与量で有意な活性を有した。
Claims (12)
- 式(I):
Pは、フェニル、キノリニル、イソキノリニル、1,2,3,4−テトラヒドロキノリニル、ベンゾイソキサゾリルまたはベンゾチアゾリルであり;
P’は、フェニル、ピリジニル、ピリミジニル、ピリダジニルまたはベンゾチアゾリルであり;
R1およびR2は、同じであっても異なっていてもよく、アルキル、アルコキシ、ハロ、−CF3、−OCF3、−OH、=O、−CN、−NO2、−SO2NH2、−SO2R3または−NR3R4であり;
R3およびR4は、同じであっても異なっていてもよく、−Hまたはアルキルであり;
mは、0または1であり;
nは、0、1、2、3、4または5であり;
Xは、NまたはCHである]
で示される化合物またはその医薬上許容される塩もしくは溶媒和物:
ただし:
4−フェニル−N−キノリン−7−イル−ピペリジン−1−カルボキサミド;
N−キノリン−7−イル−1−(5−トリフルオロメチルピリド−2−イル)−ピペリジン−4−カルボキサミド;
N−キノリン−7−イル−1−(6−トリフルオロメチルピリド−2−イル)−ピペリジン−4−カルボキサミド;
N−イソキノリン−5−イル−1−(5−トリフルオロメチルピリド−2−イル)−ピペリジン−4−カルボキサミド;および
4−(4−クロロフェニル)−N−(2−メチルベンゾチアゾール−5−イル)シクロヘキサン−1−カルボキサミド;
から選択される化合物を除く化合物。 - Pが、フェニル、キノリニル、イソキノリニル、ベンゾイソキサゾリルまたはベンゾチアゾリルである、請求項1記載の式(I)で示される化合物。
- Pがフェニルである、請求項2記載の式(I)で示される化合物。
- Pが、キノリニル、イソキノリニル、ベンゾイソキサゾリルまたはベンゾチアゾリルである、請求項2記載の式(I)で示される化合物。
- P’がフェニルである、請求項1記載の式(I)で示される化合物。
- P’がピリジニルまたはピリミジニルである、請求項1記載の式(I)で示される化合物。
- 実質的に実施例のいずれか1つに関して記載した、請求項1記載の式(I)で示される化合物またはその医薬上許容される塩もしくは溶媒和物。
- 請求項1記載の式(I)で示される化合物またはその医薬上許容される塩もしくは溶媒和物および医薬上許容される担体または賦形剤を含む医薬組成物。
- 活性治療物質として用いるための式(I)で示される化合物またはその医薬上許容される塩もしくは溶媒和物。
- ヒトを含む哺乳動物における、バニロイド(VR1)受容体の拮抗が有益である障害、特に、本発明の障害の治療または予防方法であって、その治療または予防を必要とする哺乳動物に、治療的に有効な量の請求項1に記載の式(I)で示される化合物またはその医薬上許容される塩もしくは溶媒和物を投与することを含む方法。
- バニロイド(VR1)受容体の拮抗が有益である障害、特に本発明の障害の治療または予防用の医薬の製造における、請求項1記載の式(I)で示される化合物またはその医薬上許容される塩もしくは溶媒和物の使用。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0319150.9A GB0319150D0 (en) | 2003-08-14 | 2003-08-14 | Novel compounds |
PCT/EP2004/009078 WO2005016915A1 (en) | 2003-08-14 | 2004-08-12 | Piperidine/cyclohexane carboxamide derivatives for use as vanilloid receptor modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2007502258A true JP2007502258A (ja) | 2007-02-08 |
Family
ID=28052535
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006522995A Pending JP2007502258A (ja) | 2003-08-14 | 2004-08-12 | バニロイド受容体モジュレーターとして用いるためのピペリジン/シクロヘキサンカルボキサミド誘導体 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20110059979A1 (ja) |
EP (1) | EP1660481A1 (ja) |
JP (1) | JP2007502258A (ja) |
GB (1) | GB0319150D0 (ja) |
WO (1) | WO2005016915A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009136625A1 (ja) * | 2008-05-07 | 2009-11-12 | 大日本住友製薬株式会社 | 環状アミン-1-カルボン酸エステル誘導体およびそれを含有する医薬組成物 |
WO2011058933A1 (ja) * | 2009-11-11 | 2011-05-19 | 大日本住友製薬株式会社 | 環状アミン-1-カルボン酸エステル誘導体およびそれを含有する医薬組成物 |
JP2015520752A (ja) * | 2012-05-11 | 2015-07-23 | アッヴィ・インコーポレイテッド | Nampt阻害薬としてのピリダジンおよびピリジン誘導体 |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102005038947A1 (de) | 2005-05-18 | 2006-11-30 | Grünenthal GmbH | Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln |
DE102005026194A1 (de) * | 2005-06-06 | 2006-12-07 | Grünenthal GmbH | Substituierte N-Benzo[d]isoxazol-3-yl-amin-Derivate und deren Verwendung zur Herstellung von Arzneimitteln |
WO2007042325A1 (de) * | 2005-10-13 | 2007-04-19 | Morphochem Aktiengesellschaft für kombinatorische Chemie | 5-chinolinderivate mit antibakterieller aktivität |
CN101489989A (zh) | 2006-07-13 | 2009-07-22 | 协和发酵麒麟株式会社 | 戊二烯酰胺衍生物 |
KR101605061B1 (ko) * | 2009-05-29 | 2016-03-21 | 라퀄리아 파마 인코포레이티드 | 칼슘 또는 나트륨 채널 차단제로서의 아릴 치환된 카복사미드 유도체 |
JP5712524B2 (ja) * | 2009-10-28 | 2015-05-07 | Jsr株式会社 | 液晶配向剤および液晶表示素子 |
WO2012134943A1 (en) | 2011-03-25 | 2012-10-04 | Abbott Laboratories | Trpv1 antagonists |
US8969325B2 (en) | 2011-12-19 | 2015-03-03 | Abbvie Inc. | TRPV1 antagonists |
US8796328B2 (en) | 2012-06-20 | 2014-08-05 | Abbvie Inc. | TRPV1 antagonists |
AR101704A1 (es) * | 2014-08-28 | 2017-01-04 | Otsuka Pharma Co Ltd | Compuestos heterocíclicos fusionados |
WO2017146246A1 (ja) | 2016-02-26 | 2017-08-31 | 大塚製薬株式会社 | ピペリジン誘導体 |
EA201992215A1 (ru) | 2017-03-20 | 2020-02-06 | Форма Терапьютикс, Инк. | Пирролопирроловые композиции в качестве активаторов пируваткиназы (pkr) |
US20220031671A1 (en) | 2018-09-19 | 2022-02-03 | Forma Therapeutics, Inc. | Treating sickle cell disease with a pyruvate kinase r activating compound |
EP3852791A4 (en) | 2018-09-19 | 2022-06-15 | Forma Therapeutics, Inc. | ACTIVATION OF PYRUVATE KINASE R |
DE102022104759A1 (de) | 2022-02-28 | 2023-08-31 | SCi Kontor GmbH | Co-Kristall-Screening Verfahren, insbesondere zur Herstellung von Co-Kristallen |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS53132533A (en) * | 1977-04-22 | 1978-11-18 | Beecham Group Ltd | Aniline derivative having mental stabilizing effect process for preparing same intermediate useful for preparation thereof and medical composition containing same |
JP2003192673A (ja) * | 2001-12-27 | 2003-07-09 | Bayer Ag | ピペラジンカルボキシアミド誘導体 |
JP2004506714A (ja) * | 2000-08-21 | 2004-03-04 | パシフィック コーポレーション | 新規チオ尿素化合物及びこれを含有する薬学的組成物 |
JP2004525127A (ja) * | 2001-03-09 | 2004-08-19 | スミスクライン ビーチャム パブリック リミテッド カンパニー | バニロイド受容体(vr1)アンタゴニスト活性を有する尿素誘導体 |
WO2004103954A1 (ja) * | 2003-05-20 | 2004-12-02 | Ajinomoto Co., Inc. | アミド誘導体 |
JP2005501873A (ja) * | 2001-07-31 | 2005-01-20 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | アミン誘導体 |
JP2005526723A (ja) * | 2002-02-15 | 2005-09-08 | グラクソ グループ リミテッド | バニロイド受容体モジュレーター |
JP2006505570A (ja) * | 2002-10-17 | 2006-02-16 | アムジエン・インコーポレーテツド | ベンズイミダゾール誘導体およびそれのバニロイド受容体リガンドとしての使用 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE113205T1 (de) | 1988-06-17 | 1994-11-15 | Procter & Gamble | Anwendung von vanillin-derivaten zur herstellung eines arzneimittels zur behandlung von herpes simplex-infektion. |
HU206082B (en) | 1988-12-23 | 1992-08-28 | Sandoz Ag | Process for producing capsaicin derivatives and pharmaceutical compositions comprising such compounds |
CA2017383A1 (en) | 1989-06-08 | 1990-12-08 | Raymond R. Martodam | Use of vanilloids for the treatment of respiratory diseases or disorders |
AU9079491A (en) | 1990-11-27 | 1992-06-25 | Procter & Gamble Company, The | Combinations of vanilloid compounds and phosphonate antiviral compounds for treatment of herpes infections |
US5550134A (en) * | 1995-05-10 | 1996-08-27 | Eli Lilly And Company | Methods for inhibiting bone loss |
EP0912182A4 (en) * | 1996-06-28 | 1999-12-29 | Merck & Co Inc | FIBRINOGENIC RECEPTOR ANTAGONIST PRACTICES |
US6723730B2 (en) | 2000-07-20 | 2004-04-20 | Neurogen Corporation | Capsaicin receptor ligands |
AU2001278821A1 (en) | 2000-08-21 | 2002-03-04 | Pacific Corporation | Novel thiocarbamic acid derivatives and the pharmaceutical compositions containing the same |
AU2001280229B2 (en) | 2000-08-21 | 2006-12-07 | Pacific Corporation | Novel thiourea derivatives and the pharmaceutical compositions containing the same |
JP2002088073A (ja) * | 2000-09-08 | 2002-03-27 | Yamanouchi Pharmaceut Co Ltd | 抗アンドロゲン剤 |
JP4205430B2 (ja) | 2001-03-26 | 2009-01-07 | ノバルティス アクチエンゲゼルシャフト | 疼痛を治療するための、バニロイド受容体アンタゴニストとして、使用するための縮合ピリジン誘導体 |
GB0110901D0 (en) | 2001-05-02 | 2001-06-27 | Smithkline Beecham Plc | Novel Compounds |
TWI239942B (en) | 2001-06-11 | 2005-09-21 | Dainippon Pharmaceutical Co | N-arylphenylacetamide derivative and pharmaceutical composition containing the same |
PE20030417A1 (es) | 2001-09-13 | 2003-08-06 | Smithkline Beecham Plc | Derivados de urea como antagonistas del receptor vainilloide |
WO2003045920A1 (en) * | 2001-11-27 | 2003-06-05 | Merck & Co., Inc. | 4-aminoquinoline compounds |
GB0130550D0 (en) | 2001-12-20 | 2002-02-06 | Smithkline Beecham Plc | Novel compounds |
ES2319886T3 (es) * | 2002-02-20 | 2009-05-14 | Abbott Laboratories | Compuestos azabiciclicos condensados que inhiben el sutipo 1 del receptor valinoide (vr1). |
WO2004024710A1 (en) | 2002-09-13 | 2004-03-25 | Glaxo Group Limited | Urea compounds active as vanilloid receptor antagonists for the treatment of pain |
WO2004052371A2 (en) * | 2002-12-11 | 2004-06-24 | 7Tm Pharma A/S | Cyclic quinoline compounds for use in mch receptor related disorders |
US7531558B2 (en) * | 2003-02-14 | 2009-05-12 | Glaxo Group Limited | Carboxamide derivatives |
-
2003
- 2003-08-14 GB GBGB0319150.9A patent/GB0319150D0/en not_active Ceased
-
2004
- 2004-08-12 US US10/568,028 patent/US20110059979A1/en not_active Abandoned
- 2004-08-12 EP EP04764075A patent/EP1660481A1/en not_active Withdrawn
- 2004-08-12 JP JP2006522995A patent/JP2007502258A/ja active Pending
- 2004-08-12 WO PCT/EP2004/009078 patent/WO2005016915A1/en active Application Filing
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS53132533A (en) * | 1977-04-22 | 1978-11-18 | Beecham Group Ltd | Aniline derivative having mental stabilizing effect process for preparing same intermediate useful for preparation thereof and medical composition containing same |
JP2004506714A (ja) * | 2000-08-21 | 2004-03-04 | パシフィック コーポレーション | 新規チオ尿素化合物及びこれを含有する薬学的組成物 |
JP2004525127A (ja) * | 2001-03-09 | 2004-08-19 | スミスクライン ビーチャム パブリック リミテッド カンパニー | バニロイド受容体(vr1)アンタゴニスト活性を有する尿素誘導体 |
JP2005501873A (ja) * | 2001-07-31 | 2005-01-20 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | アミン誘導体 |
JP2003192673A (ja) * | 2001-12-27 | 2003-07-09 | Bayer Ag | ピペラジンカルボキシアミド誘導体 |
JP2005526723A (ja) * | 2002-02-15 | 2005-09-08 | グラクソ グループ リミテッド | バニロイド受容体モジュレーター |
JP2006505570A (ja) * | 2002-10-17 | 2006-02-16 | アムジエン・インコーポレーテツド | ベンズイミダゾール誘導体およびそれのバニロイド受容体リガンドとしての使用 |
WO2004103954A1 (ja) * | 2003-05-20 | 2004-12-02 | Ajinomoto Co., Inc. | アミド誘導体 |
Non-Patent Citations (1)
Title |
---|
JOURNAL OF MEDICINAL CHEMISTRY, vol. 26(12), JPN6009065606, 1983, pages 1747 - 1752, ISSN: 0001491096 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009136625A1 (ja) * | 2008-05-07 | 2009-11-12 | 大日本住友製薬株式会社 | 環状アミン-1-カルボン酸エステル誘導体およびそれを含有する医薬組成物 |
CN102089277A (zh) * | 2008-05-07 | 2011-06-08 | 大日本住友制药株式会社 | 环状胺-1-甲酸酯衍生物及含有其的药物组合物 |
US8367835B2 (en) | 2008-05-07 | 2013-02-05 | Dainippon Sumitomo Pharma Co., Ltd. | Cyclic amine-1-carboxylic acid ester derivative and pharmaceutical composition containing the same |
CN102089277B (zh) * | 2008-05-07 | 2014-02-12 | 大日本住友制药株式会社 | 环状胺-1-甲酸酯衍生物及含有其的药物组合物 |
WO2011058933A1 (ja) * | 2009-11-11 | 2011-05-19 | 大日本住友製薬株式会社 | 環状アミン-1-カルボン酸エステル誘導体およびそれを含有する医薬組成物 |
JP2015520752A (ja) * | 2012-05-11 | 2015-07-23 | アッヴィ・インコーポレイテッド | Nampt阻害薬としてのピリダジンおよびピリジン誘導体 |
Also Published As
Publication number | Publication date |
---|---|
EP1660481A1 (en) | 2006-05-31 |
WO2005016915A1 (en) | 2005-02-24 |
GB0319150D0 (en) | 2003-09-17 |
US20110059979A1 (en) | 2011-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2007502258A (ja) | バニロイド受容体モジュレーターとして用いるためのピペリジン/シクロヘキサンカルボキサミド誘導体 | |
EP1425277B1 (en) | Urea-compounds active as vanilloid receptor antagonists for the treatment of pain | |
US7531558B2 (en) | Carboxamide derivatives | |
JP5411927B2 (ja) | Ccr1アンタゴニストとしてのピラゾール化合物 | |
JP3022951B2 (ja) | アロイル−ピペリジン誘導体 | |
US5935951A (en) | 1-acyl-4-aliphatylaminopiperidine compounds | |
JP3073238B2 (ja) | 1−(1,2−ジ置換ピペリジニル)−4−置換ピペラジン誘導体 | |
RU2151769C1 (ru) | Тригидрат дигидрохлорида (r)-3-(1н-индол-3-ил)-1-[n-(2-метоксибензил)ацетиламино]-2-[n-(2-(4-(пиперидин-1-ил)пиперидин-1-ил)ацетил)амино]пропана и фармацевтический состав | |
RU2285002C2 (ru) | Производное пиридина и фармацевтическая композиция на его основе | |
JP2004527571A (ja) | 複素環ウレア、それらの製造およびバニロイド受容体アンタゴニストとしてのそれらの使用 | |
JP2012526061A (ja) | バニロイド受容体リガンドとしての置換された芳香族カルボキサミドおよび尿素誘導体 | |
WO2004024710A1 (en) | Urea compounds active as vanilloid receptor antagonists for the treatment of pain | |
JP2003525928A (ja) | 新規ccr5モジュレーター:ベンズイミダゾール類またはベンズトリアゾール類 | |
JP2003528046A (ja) | フェノキシプロパノールアミン類、それらの製造および治療的使用 | |
JP2012511514A (ja) | レニン阻害剤としての3,4−置換ピペリジン誘導体 | |
JP5530430B2 (ja) | Ccr2のピペリジルアクリルアミドアンタゴニスト | |
AU714523B2 (en) | Chromone derivatives | |
DD279674A5 (de) | Verfahren zur herstellung von hydrierten 1-benzooxacycloalkyl-pyridincarbonsaeureverbindungen | |
EP1603899B1 (en) | Heterocyclic urea derivatives for the treatment of pain | |
JP2006519806A (ja) | 尿素誘導体および疼痛治療におけるバニロイド受容体拮抗剤としてのそれらの使用。 | |
WO2014142056A1 (ja) | ピロリジン-3-イル酢酸誘導体の塩およびその結晶 | |
JP2011510998A (ja) | 新規sEH阻害剤およびその使用 | |
JP2006188466A (ja) | 過活動膀胱治療薬としてのキナゾリノン誘導体 | |
JP2006502171A (ja) | アロイル−ピペリジン誘導体 | |
KR20130121891A (ko) | Ccr2의 4-치환된-사이클로헥실아미노-4-피페리디닐-아세트아미드길항제 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070802 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091215 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100311 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100318 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100831 |